GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » SciClone Pharmaceuticals (Holdings) Ltd (HKSE:06600) » Definitions » Asset Turnover

SciClone Pharmaceuticals (Holdings) (HKSE:06600) Asset Turnover : 0.38 (As of Dec. 2023)


View and export this data going back to 2021. Start your Free Trial

What is SciClone Pharmaceuticals (Holdings) Asset Turnover?

Asset Turnover measures how quickly a company turns over its asset through sales. It is calculated as Revenue divided by Total Assets. SciClone Pharmaceuticals (Holdings)'s Revenue for the six months ended in Dec. 2023 was HK$1,698 Mil. SciClone Pharmaceuticals (Holdings)'s Total Assets for the quarter that ended in Dec. 2023 was HK$4,473 Mil. Therefore, SciClone Pharmaceuticals (Holdings)'s Asset Turnover for the quarter that ended in Dec. 2023 was 0.38.

Asset Turnover is linked to ROE % through Du Pont Formula. SciClone Pharmaceuticals (Holdings)'s annualized ROE % for the quarter that ended in Dec. 2023 was 32.35%. It is also linked to ROA % through Du Pont Formula. SciClone Pharmaceuticals (Holdings)'s annualized ROA % for the quarter that ended in Dec. 2023 was 24.05%.


SciClone Pharmaceuticals (Holdings) Asset Turnover Historical Data

The historical data trend for SciClone Pharmaceuticals (Holdings)'s Asset Turnover can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

SciClone Pharmaceuticals (Holdings) Asset Turnover Chart

SciClone Pharmaceuticals (Holdings) Annual Data
Trend Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Asset Turnover
Get a 7-Day Free Trial 1.08 0.83 0.74 0.63 0.75

SciClone Pharmaceuticals (Holdings) Semi-Annual Data
Dec17 Dec18 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
Asset Turnover Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only 0.30 0.34 0.29 0.37 0.38

Competitive Comparison of SciClone Pharmaceuticals (Holdings)'s Asset Turnover

For the Drug Manufacturers - Specialty & Generic subindustry, SciClone Pharmaceuticals (Holdings)'s Asset Turnover, along with its competitors' market caps and Asset Turnover data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


SciClone Pharmaceuticals (Holdings)'s Asset Turnover Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, SciClone Pharmaceuticals (Holdings)'s Asset Turnover distribution charts can be found below:

* The bar in red indicates where SciClone Pharmaceuticals (Holdings)'s Asset Turnover falls into.



SciClone Pharmaceuticals (Holdings) Asset Turnover Calculation

Asset Turnover measures how quickly a company turns over its asset through sales.

SciClone Pharmaceuticals (Holdings)'s Asset Turnover for the fiscal year that ended in Dec. 2023 is calculated as

Asset Turnover
=Revenue/Average Total Assets
=Revenue (A: Dec. 2023 )/( (Total Assets (A: Dec. 2022 )+Total Assets (A: Dec. 2023 ))/ count )
=3451.544/( (4824.661+4375.389)/ 2 )
=3451.544/4600.025
=0.75

SciClone Pharmaceuticals (Holdings)'s Asset Turnover for the quarter that ended in Dec. 2023 is calculated as

Asset Turnover
=Revenue/Average Total Assets
=Revenue (Q: Dec. 2023 )/( (Total Assets (Q: Jun. 2023 )+Total Assets (Q: Dec. 2023 ))/ count )
=1697.854/( (4571.031+4375.389)/ 2 )
=1697.854/4473.21
=0.38

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Companies with low profit margins tend to have high Asset Turnover, while those with high profit margins have low Asset Turnover. Companies in the retail industry tend to have a very high turnover ratio.


SciClone Pharmaceuticals (Holdings)  (HKSE:06600) Asset Turnover Explanation

Asset Turnover is linked to ROE % through Du Pont Formula.

SciClone Pharmaceuticals (Holdings)'s annulized ROE % for the quarter that ended in Dec. 2023 is

ROE %**(Q: Dec. 2023 )
=Net Income/Total Stockholders Equity
=1075.664/3324.585
=(Net Income / Revenue)*(Revenue / Total Assets)*(Total Assets / Total Stockholders Equity)
=(1075.664 / 3395.708)*(3395.708 / 4473.21)*(4473.21/ 3324.585)
=Net Margin %*Asset Turnover*Equity Multiplier
=31.68 %*0.7591*1.3455
=ROA %*Equity Multiplier
=24.05 %*1.3455
=32.35 %

Note: The Net Income data used here is two times the semi-annual (Dec. 2023) net income data. The Revenue data used here is two times the semi-annual (Dec. 2023) revenue data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

** The ROE % used above is for Du Pont Analysis only. It is different from the defined ROE % page on our website, as here it uses Net Income instead of Net Income attributable to Common Stockholders in the calculation.

It is also linked to ROA % through Du Pont Formula:

SciClone Pharmaceuticals (Holdings)'s annulized ROA % for the quarter that ended in Dec. 2023 is

ROA %(Q: Dec. 2023 )
=Net Income/Total Assets
=1075.664/4473.21
=(Net Income / Revenue)*(Revenue / Total Assets)
=(1075.664 / 3395.708)*(3395.708 / 4473.21)
=Net Margin %*Asset Turnover
=31.68 %*0.7591
=24.05 %

Note: The Net Income data used here is two times the semi-annual (Dec. 2023) net income data. The Revenue data used here is two times the semi-annual (Dec. 2023) revenue data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Be Aware

In the article Joining The Dark Side: Pirates, Spies and Short Sellers, James Montier reported that In their US sample covering the period 1968-2003, Cooper et al find that firms with low asset growth outperformed firms with high asset growth by an astounding 20% p.a. equally weighted. Even when controlling for market, size and style, low asset growth firms outperformed high asset growth firms by 13% p.a. Therefore a company with fast asset growth may underperform.

Therefore, it is a good sign if a company's Asset Turnover is consistent or even increases. If a company's asset grows faster than sales, its Asset Turnover will decline, which can be a warning sign.


SciClone Pharmaceuticals (Holdings) Asset Turnover Related Terms

Thank you for viewing the detailed overview of SciClone Pharmaceuticals (Holdings)'s Asset Turnover provided by GuruFocus.com. Please click on the following links to see related term pages.


SciClone Pharmaceuticals (Holdings) (HKSE:06600) Business Description

Traded in Other Exchanges
N/A
Address
381 Middle Huaihai Road, 22nd Floor, Central Plaza, Shanghai, CHN
SciClone Pharmaceuticals (Holdings) Ltd is a biopharmaceutical company with an integrated platform for product development and commercialization. It strategically focuses on some of the fast-growing therapeutic areas with unmet medical needs in China, primarily including oncology and severe infection. It generated revenue primarily from the sale of Zadaxin to Sinopharm.
Executives
Ubs Group Ag 2201 Interest of corporation controlled by you
Zhao Hong 2101 Beneficial owner
Gl Capital Management Gp Limited
Meng Liang 2201 Interest of corporation controlled by you
Ascendent Silver (cayman) Limited 2501 Other
Ascendent Capital Partners Ii Gp Limited 2201 Interest of corporation controlled by you
Ascendent Capital Partners Ii, Gp, L.p. 2201 Interest of corporation controlled by you
Ascendent Capital Partners Ii, L.p. 2201 Interest of corporation controlled by you
Gl Partners Capital Management Ltd.
Gl China Opportunities Carry Gp Limited
Ocean Falcon Limited 2101 Beneficial owner
Central Huijin Investment Ltd. 2201 Interest of corporation controlled by you
Bank Of China Limited 2201 Interest of corporation controlled by you
Bank Of China Group Investment Limited 2201 Interest of corporation controlled by you
Gl Capital Management Gp Ii B.c I. Ltd

SciClone Pharmaceuticals (Holdings) (HKSE:06600) Headlines

No Headlines